Phase 3 of POETYK-PsA-2: -Deucravacitinib (oral TyK2i) met the primary endpoint of ACR20 at week 16 and was superior to placebo in multiple PsA domains. -Clinical efficacy maintained until week 52. -No major safety signals reported. -Notably high placebo response rates. Abstract